Skip to content

Genetic Markers of Diabetic Ulcers and Personalized Treatment Targets Research

Clinical Investigation of Genetic Markers in Diabetic Ulcers and Their Role in Personalized Treatment Targeting

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06979037
Enrollment
712
Registered
2025-05-18
Start date
2024-05-16
Completion date
2027-05-16
Last updated
2025-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Ulcers

Keywords

Diabetic Ulcers

Brief summary

This clinical trial involves collecting peripheral blood, ulcer tissue, and fecal samples from diabetic ulcer patients for bioinformatics analysis to screen genetic markers significantly associated with ulcer risk and healing differences. Furthermore, multi-omics data will be integrated to establish a diabetic ulcer risk prediction model. Based on key single nucleotide polymorphisms and their regulatory pathways, potential new drug targets for promoting healing will be explored, providing a genetic basis for personalized treatment.

Interventions

None listed

Sponsors

The First Affiliated Hospital of University of South China
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 1\) Subjects who voluntarily participate in this clinical study and sign informed consent; * 2\) Patients with type 2 diabetes and diabetic ulcers; * 3\) Disease duration ≥ 10 years or age ≥ 55 years at enrollment; * 4\) Inpatient or outpatient who can be monitored by the same investigating team throughout the duration of the study.

Exclusion criteria

* 1\) Severe vascular occlusion or impairment; * 2\) Patients with congenital heart disease, aortic dissection, or other severe cardiovascular diseases; * 3\) Patients with ulcers caused by factors other than diabetes; * 4\) Patients with severe liver and kidney dysfunction or serious neurological impairment.

Design outcomes

Primary

MeasureTime frame
Ulcer Healing TimeThree years

Secondary

MeasureTime frameDescription
Absolute Change in Ulcer AreaThree yearsAbsolute change in ulcer area over three years in cm2
Number of Amputation EventsThree years
Ulcer RecurrenceThree yearsNumber of diabetic foot ulcers with recurrence at three years
Number of Foot InfectionsThree years
Quality of Life AssessmentThree yearsThe Cardiff Wound Impact Schedule questionnaire to measure quality of life. Measure of well-being items from each scale are summated, physical symptoms, everyday living and social life. The items are rated for the extent of the experience and each item is given a number value. This allows the patients to weight the items included in the scale. The well-being scale is scored on a 5-point Likert scale, with response options from 'strongly agree' to 'strongly disagree'. All three scales are then transformed onto a minimum = 0 up to a maximum = 100, where a low score indicates worse, and a high score indicates better feeling of well-being.
Length of StayThree years
Time to Complete Wound ClosureThree years or wound closureTime to 100% wound closure utilizing Cox proportional hazards model, a statistical measure of difference of time to event (healing). The analysis will consider covariates that might influence the outcome in the trial.

Countries

China

Contacts

Primary ContactJiecan Zhou, Prof.
zhoujiecan@fsyy.usc.edu.cn+86-734-8279018

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026